Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
作者： Giovanni Butturini , Valentina Allegrini , Isabella Frigerio , Stefano Gobbo , Valeria Merz
DOI: 10.1016/J.PAN.2021.04.004
关键词: Observational study 、 Performance status 、 Oncology 、 Precision medicine 、 DNA sequencing 、 Sorafenib 、 Cancer 、 Population 、 Medicine 、 Internal medicine 、 Raf kinase
摘要: Abstract Background Pancreaticoduodenal cancer (PDC) is a group of malignant tumors arising in the ampullary region, which lack approved targeted therapies for their treatment. Methods This retrospective, observational study based on Secondary Data Use (SDU) previously collected during multicenter collaboration, were subsequently entered into predefined database and analyzed. FoundationOne CDx or Liquid, next-generation DNA sequencing (NGS) service, was used to identify genomic alterations patients who failed standard treatments. Detected described according ESMO Scale Clinical Actionability molecular Targets (ESCAT). Results NGS analysis performed 68 affected by PDC. At least one alteration ranking tier I, II, III, IV ESCAT classification detected 8, 1, 9, 12 respectively (44.1%). Ten them (33.3%) received matched therapy. Patients with I generally younger than overall population (median = 54, range = 26–71 years), had an EGOG performance status score = 0 (83.3%), uncommon histological clinical presentation. The most common mutations evidence actionability (ESCAT I-III) involved genes RAF (10.3%), BRCA (5.9%) FGFR pathways (5.9%). We present activity kinases inhibitor sorafenib RAF-mutated advanced Conclusions In PDC, feasible valuable method enabling precision oncology. profiling might be considered after treatments failure, especially young maintaining good status, order detect potentially actionable offer molecularly therapeutic approaches.
sci-hub.st 参考文章(29)
Davide Melisi, Satoshi Ishiyama, Guido M. Sclabas, Jason B. Fleming, Qianghua Xia, Giampaolo Tortora, James L. Abbruzzese, Paul J. Chiao, LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Molecular Cancer Therapeutics. ,vol. 7, pp. 829- 840 ,(2008) , 10.1158/1535-7163.MCT-07-0337
H Zhang, BL Hylander, C LeVea, EA Repasky, RM Straubinger, AA Adjei, WW Ma, None, Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models British Journal of Cancer. ,vol. 110, pp. 320- 329 ,(2014) , 10.1038/BJC.2013.754
Nils C Lehnen, Anne von Mässenhausen, Holger Kalthoff, Hui Zhou, Tim Glowka, Ute Schütte, Tobias Höller, Katarina Riesner, Diana Boehm, Sabine Merkelbach-Bruse, Jutta Kirfel, Sven Perner, Ines Gütgemann, Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma Histopathology. ,vol. 63, pp. 157- 166 ,(2013) , 10.1111/HIS.12115
ALLEN O. WHIPPLE, WILLIAM BARCLAY PARSONS, CLINTON R. MULLINS, TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER. Annals of Surgery. ,vol. 102, pp. 763- 779 ,(1935) , 10.1097/00000658-193510000-00023
Davide Melisi, Geny Piro, Anna Tamburrino, Carmine Carbone, Giampaolo Tortora, Rationale and clinical use of multitargeting anticancer agents Current Opinion in Pharmacology. ,vol. 13, pp. 536- 542 ,(2013) , 10.1016/J.COPH.2013.06.012
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014
Juliann Chmielecki, Katherine E. Hutchinson, Garrett M. Frampton, Zachary R. Chalmers, Adrienne Johnson, Chanjuan Shi, Julia Elvin, Siraj M. Ali, Jeffrey S. Ross, Olca Basturk, Sohail Balasubramanian, Doron Lipson, Roman Yelensky, William Pao, Vincent A. Miller, David S. Klimstra, Philip J. Stephens, Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes Cancer Discovery. ,vol. 4, pp. 1398- 1405 ,(2014) , 10.1158/2159-8290.CD-14-0617
Davide Melisi, Valeria Ossovskaya, Cihui Zhu, Roberta Rosa, Jianhua Ling, Patrick M. Dougherty, Barry M. Sherman, James L. Abbruzzese, Paul J. Chiao, Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity Clinical Cancer Research. ,vol. 15, pp. 6367- 6377 ,(2009) , 10.1158/1078-0432.CCR-09-0910
Mehdi Touat, Ecaterina Ileana, Sophie Postel-Vinay, Fabrice André, Jean-Charles Soria, None, Targeting FGFR Signaling in Cancer Clinical Cancer Research. ,vol. 21, pp. 2684- 2694 ,(2015) , 10.1158/1078-0432.CCR-14-2329
Peter Bailey, David K Chang, Katia Nones, Amber L Johns, Ann-Marie Patch, Marie-Claude Gingras, David K Miller, Angelika N Christ, Tim JC Bruxner, Michael C Quinn, Craig Nourse, L Charles Murtaugh, Ivon Harliwong, Senel Idrisoglu, Suzanne Manning, Ehsan Nourbakhsh, Shivangi Wani, Lynn Fink, Oliver Holmes, Venessa Chin, Matthew J Anderson, Stephen Kazakoff, Conrad Leonard, Felicity Newell, Nick Waddell, Scott Wood, Qinying Xu, Peter J Wilson, Nicole Cloonan, Karin S Kassahn, Darrin Taylor, Kelly Quek, Alan Robertson, Lorena Pantano, Laura Mincarelli, Luis N Sanchez, Lisa Evers, Jianmin Wu, Mark Pinese, Mark J Cowley, Marc D Jones, Emily K Colvin, Adnan M Nagrial, Emily S Humphrey, Lorraine A Chantrill, Amanda Mawson, Jeremy Humphris, Angela Chou, Marina Pajic, Christopher J Scarlett, Andreia V Pinho, Marc Giry-Laterriere, Ilse Rooman, Jaswinder S Samra, James G Kench, Jessica A Lovell, Neil D Merrett, Christopher W Toon, Krishna Epari, Nam Q Nguyen, Andrew Barbour, Nikolajs Zeps, Kim Moran-Jones, Nigel B Jamieson, Janet S Graham, Fraser Duthie, Karin Oien, Jane Hair, Robert Grützmann, Anirban Maitra, Christine A Iacobuzio-Donahue, Christopher L Wolfgang, Richard A Morgan, Rita T Lawlor, Vincenzo Corbo, Claudio Bassi, Borislav Rusev, Paola Capelli, Roberto Salvia, Giampaolo Tortora, Debabrata Mukhopadhyay, Gloria M Petersen, Australian Pancreatic Cancer Genome Initiative, Donna M Munzy, William E Fisher, Saadia A Karim, James R Eshleman, Ralph H Hruban, Christian Pilarsky, Jennifer P Morton, Owen J Sansom, Aldo Scarpa, Elizabeth A Musgrove, Ulla-Maja Hagbo Bailey, Oliver Hofmann, Robert L Sutherland, David A Wheeler, Anthony J Gill, Richard A Gibbs, John V Pearson, Nicola Waddell, Andrew V Biankin, Sean M Grimmond, None, Genomic analyses identify molecular subtypes of pancreatic cancer Nature. ,vol. 531, pp. 47- 52 ,(2016) , 10.1038/NATURE16965